(Q46903227)

26 December 2017

title

Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria (English)

1 reference

26 December 2017

1 reference

K C Tse

1

1 reference

26 December 2017

F K Li

2

1 reference

26 December 2017

S Tang

3

1 reference

26 December 2017

C S-O Tang

4

1 reference

26 December 2017

K N Lai

5

1 reference

26 December 2017

T M Chan

6

1 reference

26 December 2017

publication date

1 January 2005

1 reference

26 December 2017

published in

Lupus

1 reference

26 December 2017

volume

14

1 reference

26 December 2017

issue

12

1 reference

26 December 2017

page(s)

947-952

1 reference

26 December 2017

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

cites work

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2249OA

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2249OA

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2249OA

Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2249OA

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2249OA

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2249OA

Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2249OA

Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2249OA

Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2249OA

Prognostic factors in lupus nephritis. Contribution of renal histologic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2249OA

Add-on angiotensin receptor blockade with maximized ACE inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2249OA

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2249OA

Anaemia in dialysis patients as a side-effect of sartanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2249OA

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2249OA

10.1191/0961203305LU2249OA

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017